Deciphera Pharmaceuticals Completes Target Enrollment in the INTRIGUE Phase 3 Clinical Study of QINLOCK® (Ripretinib) in Patients with Second-Line Gastrointestinal Stromal TumorBusiness Wire • 11/30/20
Deciphera Pharmaceuticals, Inc. to Participate in the Piper Sandler 32nd Annual Virtual Healthcare ConferenceBusiness Wire • 11/24/20
Deciphera Presents Data from QINLOCK® (Ripretinib) Program at the Connective Tissue Oncology Society (CTOS) 2020 Virtual Annual MeetingBusiness Wire • 11/11/20
Deciphera Presents Updated Preliminary Data from DCC-3014, its CSF1R Inhibitor Program, in Tenosynovial Giant Cell Tumor Patients at the Connective Tissue Oncology Society (CTOS) 2020 Virtual Annual MeetingBusiness Wire • 11/11/20
Deciphera Pharmaceuticals, Inc. to Present at the Jefferies Virtual London Healthcare ConferenceBusiness Wire • 11/10/20
Deciphera Pharmaceuticals, Inc. (DCPH) CEO Steve Hoerter on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/08/20
Medison Pharma Enters Exclusive Distribution Agreement with Deciphera Pharmaceuticals to Commercialize QINLOCK® (Ripretinib) in a Multi-Regional AgreementPRNewsWire • 11/06/20
Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2020 Financial ResultsBusiness Wire • 11/05/20
Deciphera Pharmaceuticals, Inc. to Announce Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 5, 2020Business Wire • 10/28/20
Deciphera Presents Data from QINLOCK™ (Ripretinib) Program in Patients with Gastrointestinal Stromal Tumor at the European Society for Medical Oncology (ESMO) Virtual Congress 2020Business Wire • 09/18/20
Deciphera Presents Data from Rebastinib, its TIE2 Inhibitor Program, at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 Business Wire • 09/17/20
Deciphera Announces Publication of QINLOCK™ (ripretinib) Phase 1 Study Results in Patients with Gastrointestinal Stromal Tumor in Journal of Clinical OncologyBusiness Wire • 08/17/20
Deciphera Pharmaceuticals, Inc. to Present at the Canaccord Genuity 40th Annual Growth ConferenceBusiness Wire • 08/06/20
Deciphera Pharmaceuticals Inc (DCPH) CEO Steve Hoerter on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/05/20
Deciphera Pharmaceuticals, Inc. Announces Second Quarter 2020 Financial ResultsBusiness Wire • 08/04/20
Deciphera Pharmaceuticals, Inc. to Announce Second Quarter 2020 Financial Results and Host Conference Call and Webcast on August 4, 2020Business Wire • 07/29/20
Deciphera Announces Australian Therapeutic Goods Administration’s Approval of QINLOCK™ (ripretinib) for the Treatment of Fourth-Line Gastrointestinal Stromal TumorBusiness Wire • 07/14/20
Deciphera Announces Presentation of Analysis of Crossover Population from the INVICTUS Phase 3 Study of QINLOCK™ (ripretinib) in Patients with Fourth-Line Advanced GISTBusiness Wire • 07/02/20
Deciphera Announces Health Canada’s Authorization of QINLOCK™ (ripretinib) for the Treatment of Fourth-Line Gastrointestinal Stromal TumorBusiness Wire • 06/22/20
Deciphera Prepares To Collect Revenue After First FDA Approval: 'We Are Well-Positioned'Benzinga • 05/29/20